PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
29695672-1	2018	The objective of this study was to evaluate the efficacy of a non-selective COX inhibitor (tolfenamic acid) and a selective COX-2 inhibitor (robenacoxib) for post-operative pain control in cats.	robenacoxib	141-152	cytochrome c oxidase subunit II	Felis catus	124-129	
19161452-1	2009	This study investigated the analgesic, anti-inflammatory and antipyretic efficacy of the new COX-2 selective inhibitor robenacoxib in the cat and established pharmacodynamic (PD) parameters for these effects.	robenacoxib	119-130	cytochrome c oxidase subunit II	Felis catus	93-98	
19161452-0	2009	Use of a pharmacokinetic/pharmacodynamic approach in the cat to determine a dosage regimen for the COX-2 selective drug robenacoxib.	robenacoxib	120-131	cytochrome c oxidase subunit II	Felis catus	99-104	
35460083-4	2022	At registered dosages (2 mg/kg subcutaneously in dogs and cats, 1-4 mg/kg orally in dogs and 1-2.4 mg/kg orally in cats), robenacoxib produces significant inhibition of COX-2 whilst sparing COX-1.	robenacoxib	122-133	cytochrome c oxidase subunit II	Felis catus	169-174	
21736587-1	2012	The safety of robenacoxib, a nonsteroidal anti-inflammatory drug with high selectivity for inhibition of the cyclooxygenase (COX)-2 isoform of COX, was investigated in the cat in two randomized, blinded, placebo-controlled, parallel-group studies.	robenacoxib	14-25	cytochrome c oxidase subunit II	Felis catus	109-131	
24628410-13	2014	In vivo IC50 COX-1/IC50 COX-2 ratios were 66.9:1 for robenacoxib and 1:107 for S(+) ketoprofen.	robenacoxib	53-64	cytochrome c oxidase subunit II	Felis catus	24-29	
21736587-5	2012	Pharmacokinetic-pharmacodynamic simulations indicated that all dosages of robenacoxib were associated with marked inhibition of COX-2 at peak effect (median I(max) 97.8-99.4% inhibition) with lesser inhibition of COX-1 (median I(max) 26.8-58.3% inhibition).	robenacoxib	74-85	cytochrome c oxidase subunit II	Felis catus	128-133	
21767277-4	2012	A tissue cage model of acute inflammation was used to determine robenacoxib"s pharmacokinetics and its ex vivo and in vivo selectivity for COX-1 and COX-2 using serum TxB(2) and exudate PGE(2) as surrogate markers for enzyme activity, respectively.	robenacoxib	64-75	cytochrome c oxidase subunit II	Felis catus	149-154